Adaptimmune Therapeutics Plc Stock Today
| ADAP Stock | USD 1.19 0.02 1.65% |
Performance5 of 100
| Odds Of DistressLess than 39
|
Adaptimmune Therapeutics is selling at 1.19 as of the 2nd of May 2024; that is -1.65% down since the beginning of the trading day. The stock's last reported lowest price was 1.17. Adaptimmune Therapeutics has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Adaptimmune Therapeutics Plc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of April 2024 and ending today, the 2nd of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of May 2015 | Category Healthcare | Classification Health Care |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. The company has 255.56 M outstanding shares of which 3.41 M shares are presently shorted by private and institutional investors with about 2.55 trading days to cover. More on Adaptimmune Therapeutics Plc
Moving together with Adaptimmune Stock
| 0.69 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
| 0.7 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Adaptimmune Stock
| 0.57 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 10th of May 2024
Adaptimmune Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Adaptimmune Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Adaptimmune Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Principal CEO | Adrian Rawcliffe | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Adaptimmune Therapeutics report their recommendations after researching Adaptimmune Therapeutics' financial statements, talking to executives and customers, or listening in on Adaptimmune Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Adaptimmune Therapeutics. The Adaptimmune consensus assessment is calculated by taking the average forecast from all of the analysts covering Adaptimmune Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Adaptimmune Therapeutics' liquidity, profitability, solvency, and operating efficiency, Adaptimmune Therapeutics Plc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in June. Financial strength of Adaptimmune Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adaptimmune Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Adaptimmune Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adaptimmune Therapeutics' financial leverage. It provides some insight into what part of Adaptimmune Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adaptimmune Therapeutics Plc (ADAP) is traded on NASDAQ Exchange in USA. It is located in 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX and employs 449 people. Adaptimmune Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 306.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adaptimmune Therapeutics's market, we take the total number of its shares issued and multiply it by Adaptimmune Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Adaptimmune Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 255.56 M outstanding shares of which 3.41 M shares are presently shorted by private and institutional investors with about 2.55 trading days to cover.
Adaptimmune Therapeutics Plc currently holds about 199.67 M in cash with (141.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Adaptimmune Therapeutics Probability Of Bankruptcy
Ownership AllocationAdaptimmune Therapeutics retains a total of 255.56 Million outstanding shares. Over half of Adaptimmune Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Adaptimmune Therapeutics. Please watch out for any change in the institutional holdings of Adaptimmune Therapeutics as this could mean something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Adaptimmune Ownership Details
Adaptimmune Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of Adaptimmune Therapeutics jumping above the current price in 90 days from now is about 72.27%. The Adaptimmune Therapeutics Plc probability density function shows the probability of Adaptimmune Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.4539. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Adaptimmune Therapeutics will likely underperform. Additionally, adaptimmune Therapeutics Plc has an alpha of 0.5712, implying that it can generate a 0.57 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Adaptimmune Therapeutics to move above the current price in 90 days from now is about 72.27 (This Adaptimmune Therapeutics Plc probability density function shows the probability of Adaptimmune Stock to fall within a particular range of prices over 90 days) .
Adaptimmune Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Adaptimmune Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Adaptimmune Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Adaptimmune Therapeutics' value.| Instituion | Recorded On | Shares | |
| Rock Springs Capital Management Lp | 2023-12-31 | 2.4 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 2 M | |
| Fmr Inc | 2023-12-31 | 1.7 M | |
| Syncona Portfolio Ltd. | 2023-12-31 | 1.4 M | |
| Renaissance Technologies Corp | 2023-12-31 | 1.4 M | |
| Jpmorgan Chase & Co | 2023-12-31 | 928.2 K | |
| Redmile Group, Llc | 2023-09-30 | 715.6 K | |
| Gsa Capital Partners Llp | 2023-12-31 | 508.8 K | |
| Acuitas Investments, Llc | 2023-12-31 | 479.8 K | |
| Matrix Capital Management Company, Llc | 2023-12-31 | 39 M | |
| Nea Management Company, Llc | 2023-12-31 | 17.1 M |
Adaptimmune Therapeutics Historical Income Statement
Adaptimmune Therapeutics Plc Income Statement is one of the three primary financial statements used for reporting Adaptimmune's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Adaptimmune Therapeutics revenue and expense. Adaptimmune Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Adaptimmune Therapeutics' Interest Expense is relatively stable compared to the past year. As of 05/02/2024, Total Other Income Expense Net is likely to grow to about 9.7 M, while Other Operating Expenses is likely to drop slightly above 116.9 M. View More FundamentalsAdaptimmune Stock Against Markets
Picking the right benchmark for Adaptimmune Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Adaptimmune Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Adaptimmune Therapeutics is critical whether you are bullish or bearish towards Adaptimmune Therapeutics Plc at a given time. Please also check how Adaptimmune Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Adaptimmune Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Adaptimmune Therapeutics Corporate Directors
Adaptimmune Therapeutics corporate directors refer to members of an Adaptimmune Therapeutics board of directors. The board of directors generally takes responsibility for the Adaptimmune Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Adaptimmune Therapeutics' board members must vote for the resolution. The Adaptimmune Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Ali Behbahani | Non-Executive Independent Director | Profile | |
| Peter Thompson | Non-Executive Independent Director | Profile | |
| Elliot Sigal | Non-Executive Independent Director | Profile | |
| John Furey | Non-Executive Independent Director | Profile |
How to buy Adaptimmune Stock?
Before investing in Adaptimmune Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Adaptimmune Therapeutics. To buy Adaptimmune Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Adaptimmune Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Adaptimmune Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Adaptimmune Therapeutics Plc stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Adaptimmune Therapeutics Plc stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Adaptimmune Therapeutics Plc, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Adaptimmune Stock please use our How to Invest in Adaptimmune Therapeutics guide.
Already Invested in Adaptimmune Therapeutics Plc?
The danger of trading Adaptimmune Therapeutics Plc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adaptimmune Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adaptimmune Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adaptimmune Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Adaptimmune Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Adaptimmune Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Adaptimmune Therapeutics Plc Stock. Highlighted below are key reports to facilitate an investment decision about Adaptimmune Therapeutics Plc Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Adaptimmune Therapeutics information on this page should be used as a complementary analysis to other Adaptimmune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Adaptimmune Stock analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Adaptimmune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptimmune Therapeutics. If investors know Adaptimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptimmune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 0.3 | Quarterly Revenue Growth (0.98) | Return On Assets (0.28) | Return On Equity (1.88) |
The market value of Adaptimmune Therapeutics is measured differently than its book value, which is the value of Adaptimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptimmune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Adaptimmune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptimmune Therapeutics' market value can be influenced by many factors that don't directly affect Adaptimmune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptimmune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptimmune Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptimmune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.